Stay updated with breaking news from Richard Kapsa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and
Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present
SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical needCollaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumorsSynaffix wi...
BASEL, Jan. 19, 2023, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa
SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumorsPreclinical efficacy and tolerability studies of SOT106 show promising results across multiple solid tumor indications and a beneficial therapeutic indexSOTIO is actively exploring additional tumor ta...